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CHAPTER 1: INTRODUCTION 
 
1.1 CANCER 
 
          The simplest definition according to American cancer society [1], 
cancer is a group of diseases characterized by uncontrollable growth and 
spread of abnormal cells. If the spread is not controlled it could result in 
death of patient. Cancer is the second leading cause of death in united 
states and currently one in four deaths are due to cancer [3]. Cancer cells 
are formed due to certain abnormalities in the normal cells and they would 
divide uncontrollably even in presence of signals that normally would inhibit 
cell growth. Cancer cell properties are abnormality, uncontrollability and 
invasiveness. They divide in an uncontrollable manner and pileup into a 
non-structured mass or tumor. Tumors are said to be benign if they remain 
at their origin and considered malignant if they invade into other parts of the 
body [4, 5]. Tumors are solids or non-solid depending on the body part they 
grow. More than 80% of tumors are solid tumors and most common sites 
are breast, pancreas, ovarian, lungs, prostate and colon etc. Non-solid 
tumors usually form in blood like leukemia and lymphoma and circulate 
around the body through the blood stream. 
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PANCREATIC CANCER 
           There have been several advancements in cancer therapy from past 
4 decades in all areas of cancer. However there was not much 
improvement in 5 year survival rate of pancreatic cancer (3% in 1975 and 
6% in 2011) [3]. Pancreatic cancer is the most aggressive form of human 
cancer and only about 10% of the cases have tumor just confined to 
pancreatic region at the time of diagnosis [6]. The overall 5-year survival 
rate is lowest for pancreatic cancer (3-5%) of all major cancers. Surgery is 
an option for treatment in very few pancreatic cancer patients and it would 
only improve the survival rate up to 10 – 15%. In USA pancreatic cancer is 
the 4th leading cause of cancer deaths [6]. Metastatic pancreatic cancer 
survival rate is 3-5 months without active treatment, 6-10 months for locally 
advanced disease and which could improve to 11-15 months with surgical 
resection. Because of the aggressive nature of the tumor, only for minority 
of patients (10-15%) can potentially undergo curative surgery [7]. The 5-
year survival rate of pancreatic cancer is very low (20%) when compared to 
staging cohorts who has other cancers such as breast (98%) and colon 
(90%). So improved pancreatic cancer therapies are needed [3]. Pancreatic 
ductal adenocarcinoma is a solid tumor which forms a dense desmoplastic 
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layer around the tumor cells and this poses as a main barrier for any drug 
delivery systems to reach the cells 
        The main pathological condition in pancreatic cancer is the formation 
of dense desmoplastic layer surrounding the tumor cells. The word 
Desmoplasia is derived from the greek words desmos meaning “band” or 
“fastening” and plassein meaning to “mold” or “form”. Desmoplastic 
reaction involves overproduction of extracellular matrix proteins and 
extensive proliferation of myofibroblast-like cells [1]. This dense connective 
tissue will contain cellular components like stellate cells and extra cellular 
matrix proteins like collagen types i, iii, iv, fibronectin, laminin, hyaluronan 
and glycoprotein osteonectin. Desmoplasia reduces the elasticity of the 
tumor and thereby increases the interstitial pressure which inturn will 
decrease the rate of perfusion of chemotherapeutic agents in tumor cells 
and causes reduction in efficacy of the drugs (figure 1). Desmoplasia is the 
major contributing factors for developing chemoresistance in pancreatic 
cancer [1, 8]. Transforming growth factor β (TGFβ), basic fibroblast growth 
factor (FGF2) connective tissue growth factor (CTGF), and interleukin-1β 
(IL-1β) stimulates ECM production whereas platelet-derived growth factor 
(PDGF) stimulates the proliferation of the myofibroblast-like cell population. 
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All these cellular and non-cellular components contribute to pathogenesis 
of pancreatic cancer [1, 9]. 
 
        
               
        Currently the only curative treatment for pancreatic cancer is surgical 
resection and only about 15% of the cases detected were still in surgically 
resectable stage [10]. Surgical resection increases the survival rate to 15-
25% [11]. Chemotherapy remains the frontline approach to pancreatic 
cancer with FOLFOX (oxaliplatin and 5-fluorouracil) or Abraxane (albumin-
bound paclitaxel) and gemcitabine being the standard-of-care treatment 
modalities. Achieving higher drug concentration in tumor cells without 
affecting the normal cells is the primary goal for any cancer chemotherapy. 
FIG	  1:	  Cell-­‐cell	  interactions	  and	  ECM	  deposition	  contributing	  to	  desmoplasia	  in	  pancreatic	  cancer[2]	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Drug resistance often limits the success of chemotherapy. Many new 
chemotherapeutic approaches to pancreatic cancer are currently in clinical 
trials, including FOLFOX-6 (FOLFOX and folinic acid), FOLFOX-A 
(FOLFOX, luecovorin, and Abraxane), and numerous hedgehog inhibitors 
with gemcitabine. In advanced pancreatic cancer these approaches are 
further complicated by desmoplastic tumor properties[8]. Pancreatic cancer 
often develops drug resistance both by intrinsic and acquired mechanisms 
[12]. Resistance to gemcitabine therapy often limits the success of 
chemotherapy [13]. Cisplatin has been shown to work in gemcitabine 
resistant tumor however cisplatin resistance will be developed shortly after 
the commencement of treatment [14]. Chemoresistance can develop by 
multiple mechanisms. Biological chemoresistance could arise mainly due to 
the development of resistance to drug uptake, altered sensitivity of 
intended targets for the drug and increased efflux of the drug. Whereas 
physiological chemoresistance can occur because of the poor tissue 
vasculature which increases the interstitial pressure as well as increases 
production of extra cellular matrix proteins due to desmoplastic reaction [1]. 
Therefore, several concurrent approaches are important in pancreatic 
cancer, including targeting the tumor, penetrating the fibrotic capsule, 
localizing the release of chemotherapeutics and using multi-target 
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therapies (to overcome drug resistance). 
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1.2 CURCUMIN  
1.2.1 ORIGIN 
Curcumin (1,7-bis(4-hydroxy 3-methoxy phenyl)-1,6- heptadiene-3,5-
dione), a polyphenol, is a natural compound that is derived from turmeric, 
the powdered rhizome of the medicinal plant Curcuma longa Linn [15]. It is 
called turmeric in English, haldi in hindi and ukon in Japanese and it has 
been used in Asian medicine since the second millenium BC. Curcumin 
has been used as aromatic spice and coloring agent in Asian cooking. 
Curcumin has also been recognized in traditional indian medicine for 
treatment of various respiratory conditions like asthma, bronchial 
hyperactivity, allergy as well as anorexia, sinusitis and hepatic disease [16, 
17]. In addition to this, curcumin, along with other natural substances like 
slaked lime, has been used topically for wounds and inflammation. The 
phytochemical curcumin consists of various curcuminoids like curcumin I 
(or curcumin, ≈77%), curcumin II (demethoxycurcumin, ≈17%) and 
curcumin III (bisdemethoxycurcumin, ≈3%)[16] (figure 2).  
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FIG 2: Chemical structure of curcuminoids [18] 
        By the observation of multiple advantages of naturally occurring 
compounds in traditional medicine, researchers have further evaluated their 
studies on these compounds towards their anti-tumor efficacy. Curcumin, 
was found to have broad range of activity because of its ability to affect 
multiple intra cellular targets [19]. Several studies done on curcumin over 
the past decade has proven its profound activity as anti-inflammatory [20], 
antioxidant [21], anticarcinogenic [22], hepatoprotective [23], 
thrombosuppressive [24], cardioprotective [25], antiarthritic [26], and anti-
infectious [27] properties. To date, there were no reports of curcumin 
toxicity on either animal or human study [16]. It was found to be safe at 
even high dose of 8 grams/day during human trials and this makes it a 
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desirable candidate for cancer therapy along with reduction of the 
cytotoxicity to the normal cells [28, 29].   
1.2.2 MECHANISM OF ACTION 
          Curcumin affects all three stages of carcinogenesis: initiation, 
promotion and progression (figure 3). Curcumin exerts its action mainly by 
inhibition of transcription factor nuclear factor kappa B (NF-κB), Ap-1, β-
catenin, epidermal growth factor receptor (EGFR), human epidermal 
growth factor receptor (HER2), and STAT-3. It also affects various 
oxygenases, such as COX-2 and 5-lipoxygenase (5-LOX), inducible nitric 
oxide synthase (iNOS), cell cycle proteins (cyclin Dl and p21), cytokines 
(TNF, IL-1, IL-6, chemokines), as well as cell surface adhesion molecules 
and thereby affects several proinflammatory pathways [18, 30]. COX-2 is 
over expressed in many varieties of malignancies including pancreatic 
cancer. COX-2 mediated prostaglandin synthesis promotes the growth of 
tumor cells as well as COX-2 over expression inhibits apoptosis. This COX-
2 expression is regulated by NF-κB and curcumin was shown to inactivavte 
NF-κB. This proves that curcumin is effective in pancreatic cancer therapy 
[31]. Because of the ability of curcumin to affect different molecular 
mechanisms in cancer without much toxicity it is a very desirable candidate 
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for cancer therapy and further research.  
 
 
 
FIGURE 3: Modulation of multiple molecular targets by curcumin in cancer 
cells. Arrows represent induction/activation whereas blunt-ended lines 
represented inhibition/repression [18]. 
         Curcumin prevents the formation of reactive oxygen species and 
reactive nitrogen species through activated macrophages and neutrophils 
via blocking NF- κB activation. This is done by preventing phosphorylation 
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and degradation of inhibit kappa B alpha resulting in down regulation of 
inducible nitric oxide synthase (iNOS) gene transcription. Reactive oxygen 
species causes lethal mutations. Therefore by preventing the formation of 
the later curcumin prevents the initiation of cancer [30, 32]. NF- κB pathway 
also plays a primary role in tumerogenesis. NF- κB binds to DNA and 
causes transcription of genes involved in tumerogenesis such as 
apoptotsis, inflammation and angiogenesis. I-Kappa B kinase (IKK) causes 
the activation of NF- κB via phosphorylation of inhibitory molecules. 
Curcumin blocks IKK activation and inhibits NF- κB signaling. Thus, 
curcumin decreases the survival and induces the apoptosis of pancreatic 
cancer cells [17, 18]. Although curcumin was shown to be effective against 
breast, pancreatic, prostate cancer, etc.  it’s limited bioavailability limits its 
therapeutic value. Numerous curcumin analogs have been made to 
overcome this bioavailability issue. Difluorinated curcumin (CDF) is one 
such analog of curcumin and the present study utilized CDF as the main 
drug. 
1.2.3 CURCUMIN AS CHEMOSENSITIZER 
           Curcumin exerts chemo sensitization properties on various 
chemoresistant cancers by increasing the apoptosis of cancer cells along 
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with its cancer preventive property. Data from the earlier in vitro and in vivo 
studies has reported curcumin chemosensitizing properties on multiple 
cancers. Curcumin potentiates the affect of gemcitabine in pancreatic 
cancer[33]. Curcumin was shown to potentiate cytotoxic effects of 
doxorubicin, 5-FU and paclitaxel against prostrate cancer cells [34]. 
Curcumin also enhanced cytotoxicity of cisplatin against ovarian cancer 
cells [35]. Curcumin also proved to potentiate the activity of drugs such as 
gemcitabine, celecoxib, oxaliplatin, docetaxel in vivo [16]. Curcumin’s 
chemosensitizing effects on multiple cancers used alone or in combination 
with other drugs makes it a more desirable drug for cancer therapy. 
1.2.4 PHARMACOKINETICS OF CURCUMIN 
           The anti-cancer activity and therapeutic potential of curcumin is 
hampered by its poor absorption, rapid metabolism and biliary clearance. 
Curcumin has very low oral bioavailability. Absorbed curcumin undergoes 
rapid first pass metabolism and biliary clearance [17]. Phase II clinical trails 
on patients with advanced pancreatic cancer have showed that curcumin 
has potency against pancreatic cancer, but high levels of exposure were 
required [36].  
         Several drug delivery approaches have been utilized to improve 
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curcumin bioavailability by incorporating it into nanoparticle formulations. 
Oral bioavailability of curcumin has been improved by incorporating it into 
liposomes [37], micelles [38, 39], and nanoparticles [40-45]. The 
nanoparticle formulation of Poly (lactic-co-glycolic) acid encapsulated 
curcumin improved its oral bioavailability up to 9 fold when compared to 
free curcumin [46]. An in vivo report showed that one micelle formulation of 
curcumin improved its oral bioavailability upto 162 fold [39]. This 
improvement in oral bioavailability is due to PEG (polyethylene glycol) 
stabilization of nanoparticles which in turn are expected to increase the 
circulation time of nanoparticles. There was a report which desribed that 
PLGA encapsulated curcumin has higher anti-cancer activity against 
cisplatin resistant metastatic cancer cells when compared to free curcumin 
[45]. All these studies improved oral bioavailability of curcumin to a certain 
extent, but once curcumin is released it is susceptible for rapid metabolism 
and clearance. Therefore target tissue bioavailability is still a concern and 
requires further improvement. 
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1.3 DIFLUORINATED CURCUMIN (CDF) 
1.3.1 ORIGIN AND MECHANISM OF ACTION 
              Recently some chemical derivatives of curcumin were shown to be 
more effective than free curcumin in eradicating chemo resistant cancer 
cells. A group recently studied the effect on introduction of bioisosteric 
fluoro substitution in curcumin and found out that because of higher 
metabolic stability of the C–F bond than C–H or C–OH, metabolic 
breakdown of curcumin slowed down and thereby the pharmacokinetic 
profile was improved [47, 48]. A novel synthetic analog of curcumin, 3,4-
difluoro-benzo curcumin named as Difluorinated curcumin or in short CDF 
(figure 4) was developed by Fazlul H. Sarkar and his group to address the 
issues associated with poor bioavailability of curcumin [48].  
FIGURE 4: Structure of Difluorinated curcumin [31]   
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            CDF also binds to active site of COX-2 similar to curcumin and its 
mechanism of action is very similar to that of curcumin [31]. Molecular 
docking studies showed that CDF has not induced any major steric 
changes when compared to the parent drug curcumin and also reduce NF- 
κB signaling and decrease the levels of PGE2, which is consistent with 
curcumin [49]. CDF was found to be more effective than curcumin in 
reducing the cell viability of pancreatic cancer cells by inducing apoptosis 
by reducing Akt, cyclooxygenase-2, prostaglandin E2, vascular endothelial 
growth factor, and NF-κB DNA binding activity [50]. In a gemcitabine 
resistant pancreatic cell line, CDF upregulated miR-200 and downregulated 
the miR-21 (signature of tumor agressiveness) which is otherwise 
upregulated, causing increased expression of PTEN, a well known tumor 
suppressor gene [50, 51].  
1.3.2 PHARMACOKINETIC ANALYSIS  
          CDF has 16-fold higher bioavailability when compared to curcumin 
with equivalent bioactivity and has higher pancreatic distribution [52]. This 
increased bioavailability makes it a desirable candidate for study. A recent 
study reported that a CDF:β-cyclodextrin complex lowered the IC50 values 
against multiple cancer cell lines of pancreas, breast and prostate cancer 
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[53]. In the present study we are focusing on making polymeric micelles 
incorporating CDF to improve its bioavailability. 
1.4 POLYMERIC MICELLES 
         Polymeric micelles (figure 5) are amphiphilic in nature and composed 
of distinct hydrophilic and hydrophobic regions. When the amphiphilic 
polymer gets exposed to water, they phase separate forming a hydrophilic 
outer surface with a hydrophobic inner core forming a supramolecular 
core/shell structure [54, 55].  
 
 
FIGURE 5: Design of a polymeric micelle carrier system[55] 
            These bock copolymer micelles resemble traditional low molecular 
weight surfactant micelles. Polymeric micelles are formed due to the self 
assembly of the copolymer in a solvent which is favorable for one part of 
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the copolymer and poor for the other. This self-assembly forms micelles. 
         However there are certain differences associated with this 
macromolecule self assembly when compared to low molecular weight 
surfactants. The first one being low molecular weight surfactants exist as 
monomer in the initial stage where there is no association, whereas for 
copolymers this term would cause confusion and these are called 
“unimers”. The hydrophobic region of these unimers are compacted into a 
highly coiled structure even in the nonaggregated state and these are 
called “unimolecular micelles” [56]. Another difference would be with the 
implication of use of the term “micelle”. For low molecular weight 
surfactants the micelle formation does not significantly vary with 
concentration, temperature etc., whereas the micelle formation with a 
copolymer is much more complex and it is a continuously changing entity. 
Therefore the word ‘aggregate’ or ‘micelle’ are commonly used 
interchangeably [56, 57].  
          The most important physicochemical characteristic of polymeric 
micelles is their high structural stability which can be attributed to the 
polymeric chain entanglement in the inner core of micelles. Two aspects of 
stability of micelles are static and dynamic [55, 58]. Static stability can be 
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explained as the equilibrium between a single polymer chain and a 
micelle’s structure or by the critical micelle concentration (CMC) [59]. 
Generally, polymeric micelles have a low CMC value when compared to 
micelles formed with low molecular weight surfactants. The other aspect, 
dynamic stability, can be explained by the low dissociation rate of polymeric 
micelles. This is much more important characteristic than the static stability 
for in vivo drug delivery applications where the micelles have to undergo 
metabolism, excretion as well as interact with a lot of biological fluids and 
molecules such as lipids and proteins etc. to keep them intact in this non-
equilibrium conditions. Although polymeric micelles may share the root 
word “micelles” they are much different than the traditional low molecular 
weight surfactant micelles physicochemical properties which is critical for in 
vivo drug delivery application [55, 58, 60].  
1.4.1 ADVANTAGES OF MICELLES 
         Polymeric micelles are very small in size from 10 nm to 200 nm with a 
very narrow size distribution. Liver and spleen are a part of mononuclear 
phagocytic system (MPS) usually take up nanoparticles, depending on their 
surface characteristics and size. The present micelles bear PEG on their 
surface, which is hydrophilic and prevents them from opsonisation. This 
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property is advantageous for penetration into tumor cells. A phenomena 
that supports the tumor uptake is enhanced permeation and retention effect 
(EPR) leading to higher concentration at tumor site and thereby reduces 
toxicity [55, 61]. The small size of micelles also helps in escaping the 
clearance by the mono phagocytic system [62]. Since most of the drugs are 
of low molecular weight, incorporating them into stealth nanoparticles such 
as micelles can increase their bioavailability. Stealth nanoparticles have the 
ability to evade clearance by the body and can circulate for extended 
periods of time. The drug can be either chemically conjugated to the 
hydrophobic core part of the polymer or it can be physically entrapped by 
hydrophobic interaction between the hydrophobic drug and the polymer. 
Polymeric micelles can incorporate large number of hydrophobic drugs in 
their core and thereby increase the water solubility of these hydrophobic 
drugs. Another advantage with micelles is the ability to incorporate two or 
more drugs together in one formulation of micelles so these drugs can be 
delivered simultaneously which is an added advantage for chemotherapy 
especially in case of multi drug resistant tumors. Micelles can be utilized 
both for passive and active targeting. Passive targeting takes advantage of 
the size and surface properties of micelles, which is hydrophilic and causes 
them to circulate for a long time in the body. This longer circulation time 
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takes the advantage of EPR effect in tumors. Whereas for active targeting 
the outer surface of micelles can be modified by adding certain ligand or 
the substrate like some antibodies or antigens for the markers present on 
tumor and thus making the drug delivery specific to the tumor cells. 
1.5 TESTING THE CHEMOSENSITIZING ABILITY OF CDF 
        In order to test the chemosensitizing ability of CDF, the model drug we 
chose for this study is paclitaxel. Since it is hydrophobic it can be readily 
encapsulated with CDF in micelles. There were several reports of taxane 
resistance in ovarian cancer patients [63]. So we chose ovarian cancer cell 
line SKOV3 which is paclitaxel resistant for testing the synergy. We tested 
the synergy between CDF and paclitaxel by coencapsulating CDF and 
paclitaxel together in one formulation along with micelles encapsulating 
CDF and paclitaxel individually. 
1.5.1 PACLITAXEL, ORIGIN AND MECHANISM OF ACTION  
          Paclitaxel was isolated in 1967 from the bark of taxus brevefolia 
(northwest pacific yew tree) by Monroe E. Wall and Mansukh C. Wani and 
they named it taxol. It was later discovered that the endophytic fungi on the 
bark produced taxol. The first commercial formulation was developed by 
Bristol-Myers Squibb Company with the generic name as paclitaxel and 
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sold under the trademark Taxol  [64, 65]. A newer formulation has been 
developed in which it is bound to albumin and sold under the trademark 
Abraxane . 
         Paclitaxel is crystalline white powder with empirical formula as 
C47H51NO14. It is highly lipophilic and is insoluble in water. Thus, extensive 
research is being done on incorporating paclitaxel into different kinds of 
nanoparticle formulations to improve its bioavailability. Paclitaxel is 
approved to be used alone or with other drugs for the treatment of breast 
cancer, non small cell lung cancer, ovarian cancer and AIDS related Kaposi 
sarcoma [66].  
         The mechanism of action of paclitaxel involves binding to tubulin and 
inhibiting the disassembly of the microtubules and thereby inhibiting cell 
division, blocking the cell growth [67].  
       Nanoparticles provide advantages in chemotherapy via increasing 
bioavailability of drugs by slow clearance, accuracy and efficient targeting 
[68]. However chemoresistance has been observed in various types of 
cancers including breast, lung and ovarian cancer [65]. Various potential 
drug delivery systems have been developed for paclitaxel. Complex 
nanoparticles codelivering paclitaxel and twist shRNA was shown to inhibit 
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metastasis and increased cellular uptake in metastatic breast cancer cell 
lines [69]. Use of fibroblast growth factor receptor inhibitor along with 
paclitaxel was shown to have a synergistic effect in endometrial cancer 
cells [70]. A study reported that the use of combination of etoposide and 
paclitaxel against osteosarcoma showed a synergistic effect in the 
combination when compared to the drugs used alone by upregulation of 
Fas expression and apoptosis induction [71]. Another study demonstrated 
the synergy between paclitaxel and gelomulide-k, a caspase independent 
cell death inducing agent in a breast cancer cell line [72]. Cremophor El 
(CrEL) is a formuation vehicle, an integral part of paclitaxel chemotherapy. 
It was found to have important clinical implications associated with severe 
anaphtlactoid hypersensitivity reactions, hyperlipidemia and peripheral 
neuropathy. Alternative approaches are recommended to allow better 
control of toxicity of the treatment [73]. 
1.5.2 POSSIBLE MECHANISM OF SYNERGY BETWEEN CDF AND          
PACLITAXEL 
          In the present study we chose the cell line SKOV3, which is a 
paclitaxel resistant ovarian cancer cell line to test for synergy. We also 
tested synergy in pancreatic cancer cell line BXPC3, which is paclitaxel 
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sensitive.  
           In ovarian cancer more than 70% of the patients develop resistance 
to taxane therapy. Multi drug resistance (MDR) is a significant challenge 
occurring in cancer chemotherapy [2, 74]. Incorporating two or more 
different drugs in the same formulation will provide synergy and reduce the 
development of resistance. Although there are several mechanisms by 
which resistance can develop in cancer, MDR resistance is developed 
mainly because of upregulation of the ABC binding cassette (ABC super 
family of transporters), which is a frame work of membrane bound proteins 
that act as efflux pumps for drugs and thereby the drug concentration 
cannot be achieved above cytotoxic level in the cells, which reduces the 
efficiency of the drug. P- glycol protein (P-gp), ABCG2 and MRP-1 are the 
major proteins belong to ABC transporter family. P-gp is the major protein 
involved for MDR against taxanes, vinca alkaloids and anthracyclines [75].  
A strategy to overcome MDR is to enhance systemic drug delivery by 
incorporating the drug into nanoparticles and also to deliver multiples drugs 
at the same time. Micelles are a type of nanoparticle system where 
incorporation of two or more drugs can be done and it also enhances the 
systemic circulation of the drug for long time because of the hydrophilic 
surface layer. The general rationale for employing combination therapy is 
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twofold. First, cancer cell mutations can be delayed and second, they can 
provide high therapeutic efficacy and higher target selectivity. Since CDF 
has pleiotropic effects in cancer therapy where it can act on various stages 
of cancer development. The main mechanism relies on its effects on 
transcriptional nuclear factor kappa B (NF-κB), which is master regulator in 
cell apoptosis, inflammation, proliferation and resistance. Curcumin was 
reported to down regulate three major ABC transporters including P-gp, 
ABCG-2 and MRP-1 [76]. So combining this pleiotropic effect of CDF along 
with micelle formulation and providing multi drug delivery will cause a 
synergistic effect in cancer therapy [77]. Paclitaxel, a cell cycle specific 
drug as it mainly acts on the cell division process. It prevents the formation 
of new cancer cells and CDF acts by increasing apoptosis of the formed 
cancer cells. Thus combining paclitaxel and CDF has a possibility of 
demonstrating synergism in cancer cell lines and potentially cancer in vivo. 
           The main objective of this study was to make a copolymer of PLGA 
and PEG with a disulfide bond and make micelles with that copolymer 
incorporating both CDF and paclitaxel to test for synergistic therapeutic 
effects in pancreatic (BXPC-3) and ovarian (SKOV-3) cancer cell lines. 
CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS 
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2.1 Hypothesis: localized pancreatic cancer is a morbid form of cancer 
with a 5-year survival rate of only 20%. The dense desmoplastic layer 
surrounding the solid tumor cells is the main barrier for delivery of drugs. 
Curcumin Difluorinated (CDF) was found to have a more suitable 
pharmacokinetic profile than curcumin and it also acts as a chemo 
sensitizer for various chemotherapeutic drugs. In light of this idea I 
hypothesize that PLGA-S-S-PEG micelles coencapsulating CDF and 
paclitaxel will release the drug in presence of elevated protease levels of 
the tumor in a controlled manner by coordinating the release of CDF and 
paclitaxel resulting in a highly efficacious synergistic cancer therapy. 
2.2 Specific aims 
1. To fabricate polymeric micelles (PEG-SS-PLGA) coencapsulating 
CDF & paclitaxel  
            Micelles are one of the promising drug delivery systems, which can 
incorporate one or more hydrophobic drugs in their core thereby increasing 
the solubility of drugs. In the present study we will synthesize a copolymer 
CDF-PLGA-SS-PEG, which will be used to make micelles coencapsulating 
CDF and paclitaxel. This project utilizes many innovative approaches which 
include the use of a novel curcumin derivative, CDF, which has an 
improved biological stability and potency compared to curcumin. A stealth 
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micelle formulation that evades the MPS with tumor specificity because of 
the presence of a disulfide bond which breaks only at elevated protease 
level which is in tumor. Lastly it provides multi-therapy delivery of CDF and 
paclitaxel to synergistically overcome resistance.  
2.Test the formulations for synergistic therapeutic efficacy in BXPC3 
(pancreatic cancer) and SKOV3 (ovarian cancer) cell lines.  
                  The proposed formulation will be utilized to coadminister CDF 
and paclitaxel in a controlled manner to overcome drug resistance. This 
novel formulation will protect CDF and paclitaxel, reduce the exposure of 
normal cells to paclitaxel (to reduce toxicity and increase the therapeutic-
index), prolong circulation and promote tumor-specific release of PEG 
molecules followed by controlled degradation-dependent release of CDF 
and Paclitaxel in tumor. We will test the therapeutic efficacy and synergy in 
BXPC-3 (paclitaxel sensitive) and SKOV-3 (paclitaxel resistant) cell lines.  
 
 
 
 
 
CHAPTER 3: MATERIALS AND METHODS 
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3.1 Materials 
         Methoxy poly (ethylene glycol) thiol (PEG-SH, Mw 5000) was bought 
from Jenken Technology (Beijing, China). Poly (D,L-lactide-co-glycolide) 
(PLGA) was purchased from Boehringer Ingelheim (502H, Ingelheim am 
Rhein, Germany). Cysteamine (2-Amino ethanethiol), N, N’ – Dicyclohexyl 
carbodiimide (DCC), 2-Dimethil amino pyridine (DMAP), N-Hydroxy 
succinimide (NHS) and Glutathione (GSH) is obtained from ACROS 
organics (Morris Plains, newjersy, USA). Tetrahydrofuran (THF) was 
purchased from Pharmaco-AAPER (Brookfield, CT, USA). Phosphate 
buffered saline (PBS, pH 7.4) was bought from Fisher Bioreagents (Fair 
Lawn, NJ, USA). Snake skin dialysis tubing (MWCO 3,500) was bought 
from Fisher Scientific (Rockford, IL, USA). 3-(4,5-Dimethylthiazolyl-2)-2,5-
diphenyl tetrazolium bromide (MTT) was purchased from MP Biomedicals, 
LLC (Solon, OH, USA). All the reagents used were of Paclitaxel was 
obtained from LC Laboratories (Woburn, MA, USA). Acetonitrile, acetone, 
methanol were purchased from Fisher Scientific (Rockford, IL, USA) and 
are of HPLC grade. CDF and the pancreatic cancer cell line BXPC-3 were 
gifted by Dr. Fazlul Sarkar, Department of Pathology, WSU / Barbara Ann 
Karmanos Cancer institute. The ovarian cancer cell line SKOV-3 were 
gifted by Dr. Olivia Merkel, Department of Pharmaceutical Sciences, 
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Eugene Applebaum College of Pharmacy and Health Sciences, Wayne 
State University.  
          Both cancer cell lines BXPC-3 and SKOV-3 were maintained in 
RPMI- 1640 (ATCC, Manassas, VA, USA) supplemented with 10% fetal 
bovine serum (FBS), 100 units/ml Penicillin and 100 µg/ml Streptomycin. 
Cells were cultured in a 5% CO2-humidified atmosphere at 37 °. 
3.2 METHODS 
3.2.1 Fabrication of micelles encapsulating CDF, Paclitaxel and 
coencapsulating both CDF & paclitaxel 
3.2.1.1 Synthesis of PEG-SS-PLGA-CDF 
        Briefly, 1 g (0.1 mmol) of PEG-SH (Mw 5000) and 0.77 g (10 mmol) of 
cysteamine were dissolved in methanol and allowed to react at room 
temperature by continuous stirring for 24 hours to form PEG-SS-NH2 
(figure 7). Then the reaction mixture was dialyzed against methanol for two 
days and collected upon freezing and lyophilization for 48 hours to remove 
excess solvent.  
         For the preparation of the CDF-PLGA conjugate (figure 6), equimolar 
ratios of CDF (33.43 mg, 0.1 mmol) and PLGA-COOH (679 mg, 0.1mmol) 
were dissolved in 10 ml of THF in presence of 0.2 mmol DCC and 0.2 
mmol DMAP at room temperature by continuous stirring for 24 hours. Then 
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the CDF-PLGA conjugate was precipitated out with petroleum ether and 
centrifuged at a speed of 10000 rpm to collect the precipitate. To purify the 
formed conjugate, the precipitate was dissolved in methylene chloride and 
again precipitated out with petroleum ether. This purification step was 
repeated out 3 times. Final sample was lyophilized after dissolving in 5 ml 
of methylene chloride. 
 
FIGURE 6: CDF-PLGA conjugate formation 
          To synthesize CDF-PLGA-SS-PEG (figure 7), 0.05 mmol PEG-SS-
NH2 and 0.05 mmol PLGA-CDF were dissolved in 10 ml of methylene 
chloride in presence of DCC & NHS and reacted for 24 hours with 
continuous stirring. Then the formed conjugate was precipitated out with 
petroleum ether and centrifuged at a speed of 10000 rpm to collect the 
precipitate. To purify the formed conjugate, the precipitate was dissolved in 
methylene chloride and again precipitated out with petroleum ether. This 
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purification step was repeated out 3 times. The final sample was lyophilized 
after dissolving in 5 ml of methylene chloride. 
 
 
FIGURE 7: PEG-SS-NH2 and CDF-PLGA-SS-PEG formation 
3.2.1.2 Characterization of conjugates 
          The Fourier - transformation infrared absorption (FTIR) spectra were 
recorded for the synthesized conjugates using an FTIR spectrometer 
(Jasco FTIR-4200, Tokyo, Japan) and a sample holder (Jasco ATR 
PRO450-S) at 400-4,000 cm-1 at room temperature. The dried samples 
were analyzed directly with the FTIR spectrometer. The nuclear magnetic 
resonance (1H-NMR) spectrum was recorded on a Varian spectrometer 
operating at 400 MHZ using CDCl3 (Deuterated chloroform) as the solvent. 
Thin layer chromatography (TLC) was performed for the CDF-PLGA 
conjugate using ethyl acetate : n-hexane  in the ratio of 1:1 was used a 
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mobile phase. Acetone was used as stationary phase. Two drops were 
made separately on a TLC plate containing CDF and the CDF-PLGA 
conjugate dissolved in acetone. The results were observed under uv light. 
3.2.1.3 Preparation of CDF-PLGA-S-S-PEG micelles encapsulating 
CDF and/or Paclitaxel  
         All Micelle formulations were prepared by phase inversion using 
dialysis. A solution of 100 μg/ml of CDF-PLGA-S-S-PEG was prepared in 
THF. To make CDF loaded micelles 10 wt% CDF (0.3 mg) was added to 
the conjugate solution. Similarly, to make paclitaxel-loaded micelles 10 wt% 
of (0.3 mg) paclitaxel was added to the conjugate solution in THF. For both 
CDF and paclitaxel loaded micelles, 10 wt% of CDF (0.3 mg) and paclitaxel 
(0.3 mg) were added to the conjugate solution. Micelles were prepared by 
adding 100 μg/ml of the conjugate solution into 1 ml of deionized water  
which was under stirring at 1200 rpm. Then the emulsion was transferred 
into a dialysis bag and dialyzed against water for 24 hours by replacing with 
fresh water at 2 hour intervals to remove the organic solvent and form 
micelles. Since both CDF and paclitaxel are hydrophobic they will readily 
be encapsulated within the hydrophobic core of micelles.  The micelles 
were collected after lyophilization. 
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3.2.2 Morphological and physicochemical characterization of micelles 
3.2.2.1 Percentage Drug loading and percentage encapsulation 
efficiency for micelles 
        To determine the CDF content in micelles, 5 mg micelles were taken 
and dissolved in 5ml acetone and filtered and analyzed for CDF content on 
a Varian CARY 50 Bio / UV-VIS spectrophotometer at 355 nm. A standard 
curve of CDF in acetone was made and used for calculating drug content 
(table 1). 
           To determine the paclitaxel content in micelles, 5 mg of micelles 
were taken and dissolved in 5ml of acetonitrile and was filtered and 
analyzed for paclitaxel content by HPLC. The mobile phase consisted of 
water/acetonitrile in the ratio of 40:60 v/v. An ODS hypersil column with 250 
× 4.6 (mm) in dimensions was used. The column temperature was 
maintained at 25 °C. The flow rate was set at 1.0 ml/min and the detection 
wavelength was 228 nm. The sample solution was injected at a volume of 
10 µL. The standard curve for paclitaxel was made with the same HPLC 
method using acetonitrile as solvent and was used for calculating drug 
content (table 2). 
 
Percentage  drug  loading  content = Weight  of  drug  in  micellesTotal  weight  of  micelles ×100 
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Percentage  entrapment  efficiency = Weight  of  drug  in  micellesWeight  of  initial  drug  taken×100 
3.2.2.2 Micelle size and zeta potential 
             The particle size of micelles was determined by reconstituting 
micelles in DI water to make 0.1% w/v dispersion. This was subjected to 
size analysis by using a 90Plus Particle Size Analyzer (Brookhaven 
Instrument Corporation). Mean values were calculated. 5 runs for each 
formulation were recorded. 
             The morphology and size of micelles were studied using an atomic 
force microscope (AFM) Nanoscope III (Digital instruments/Veeco, 
Plainview, Santa Barbara, CA, USA) with an E scanner probe in the 
tapping mode. A drop of micelle suspension in DI water was put onto a 
coverslip and dried in a dessicator and observed by AFM. 
          The zeta potentials of micelles were determined by making a 0.1% 
w/v dispersion in deionized water and subjected to zeta potential analysis 
on a 90plus particle size analyzer (Brookhaven instrument corporation). 
Mean values were calculated. 10 runs for each formulation were recorded.  
3.2.2.3 Critical micelle concentration (CMC) determination  
             PLGA-S-S-PEG polymer can self assemble to form micelles due to 
the presence of the hydrophobic PLGA block, which aggregates in water to 
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form the core of the micellar structure with hydrophilic PEG as the outer 
layer. This micelle formation is commonly monitored by changes in the 
fluorescence spectrum of a pyrene probe, which preferably partitions in the 
micelle core. The encapsulation causes changes in the photophysical 
properties of the nanoparticle under investigation. With this method we 
monitor the changes in the ratio of pyrene emission spectra intensities at λ 
= 372 nm and at λ = 384 nm due to the migration of pyrene into the more 
hydrophobic region of newly formed micelles from the aqueous media [78, 
79]. The concentration of pyrene in the aqueous media was 0.2 µg/ml. The 
concentration of copolymer varied from 1 to 200 µg/ml. The micelles are 
formed in presence of the same concentration of pyrene with varying 
concentrations of polymer. These solutions were kept at room temperature 
under continuous stirring to allow the organic solvent to evaporate while 
forming micelles. Then fluorescence spectra were recorded with an 
excitation wavelength of 334 nm and emission fluorescence at 372 nm and 
384 nm using a Fluoromax-3 Spectro Fluorometer (Horiba scientific). By 
plotting I372/I384 versus the logarithm of the concentration of CDF-PLGA-S-
S-PEG, sigmoidal curves were obtained where a sharp increase of the 
fluorescence intensity ratio (I372/I384) was observed with increase in 
copolymer concentration. 
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3.2.3 Invitro drug release studies 
      The drug release profiles of CDF and paclitaxel loaded micelles were 
studied by a dialysis method. Lyophilized micelles of 5 mg containing 
encapsulated CDF and paclitaxel are suspended in 5 ml of 0.5% tween 80 
PBS at pH 7.4 and transferred to a dialysis tube. Then the tubes were 
immersed in 25 ml of release media (PBS without GSH, 20 µM GSH, 5 mM 
GSH, 20 mM GSH) 0.5% tween and also in PBS without GSH as a control 
and were gently shaken. At predetermined intervals one ml of two samples 
were collected from each group and lyophilized. The release medium was 
replaced with the same amount of new media. One sample was used for 
CDF analysis by UV-VIS spectrophotometer and the other one was used 
for paclitaxel analysis by HPLC (waters 2695 with waters 2996 photodiode 
array detector). The in vitro release profile of the free drug was also studied 
in 0.5% tween containing PBS.  
3.2.4 Cell culture studies 
3.2.4.1 Invitro cytotoxicity studies 
            These studies were done in both the BXPC-3 (pancreatic cancer) 
cell line and the SKOV-3 (human ovarian carcinoma) cell line. In vitro 
cytotoxicity of all the formulations of CDF micelles, paclitaxel micelles and 
micelles encapsulating both CDF and paclitaxel were evaluated in both cell 
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lines. Both cell lines were cultured in RPMI-1640 medium containing 10% 
fetal bovine serum and 1% penicillin-streptomycin. 
          In vitro cytotoxicity was evaluated by 3- (4,5-dimethylthiazol-2-yl)-2,5-
dipheny-ltetrazolium bromide (MTT) assays for both cell lines. The same 
procedures were followed for both cell lines. The cells were seeded into 96-
well plates at a density of 5000 cells per well and incubated at 37 °C in 
humidified atmosphere with 5% CO2 for 24 hours. Then the media was 
removed and cells were treated with media containing various drug 
concentrations of CDF and/or paclitaxel. BXPC-3 cells were tested for 
paclitaxel in the concentration range of 1000 nM to 0.001 nM for free drug 
as well as micelle formulations and for CDF in the concentration range of 5 
µM to 0.0002 µM for free drug and micelle formulations. Similarly SKOV-3 
cells were tested for paclitaxel in the range of 5 µM to 0.001 µM and CDF 
in the range of 50 µM to 0.2 µM for free drug and micelle formulations. The 
same procedure was followed for both cell lines using control micelles 
without any drug. The cytotoxicity was checked at three time points after 
drug exposure at 24 h, 48 h and 72 h. After specified durations, 22 µL of 5 
mgmL-1 of MTT prepared in PBS was added to each well. The plate was 
incubated for 2 h at 37 °C allowing viable cells to metabolically reduce 
yellow colored MTT into the purple colored formazan compound. At the end 
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of the 2 h period the medium was removed from the wells and 100 µL of 
dimethylsulfoxide (DMSO) was added to dissolve the formazan crystals 
and the plate was shaken for 20 min. The optical density (OD) was 
measured 595 nm with a Synergy H1 hybrid reader (Biotek). Cell viability 
(%) was calculated as (OD of test group/OD of control group) × 100.  
3.2.4.2 Evaluation of combination effect of CDF and paclitaxel 
           The statistical analysis of the drug combination effect was done by 
the Chou-Talalay method [80]. This method is based on the median-effect 
equation that describes the dose-effect relationship in a most simple way 
as shown below 
                                                         !!!! = !!! ! 
Where D is the dose (or concentration) of a drug, fa is the fraction affected 
by D and fu is the fraction unaffected (i.e., fu = 1 - fa). Dm is the median-
effect dose (IC50 incase of cell killing) that inhibits the system under study 
by 50%, and m is the coefficient signifying the shape of the dose-effect 
relationship, where m = 1, > 1, and < 1 indicate hyperbolic, sigmoidal, and 
flat sigmoidal dose-effect curves, respectively [80, 81].  
            The median effect equation can be extended to multiple drugs with 
mutually exclusive drug effects, for example a combination of two drugs (D1 
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and D2), the equation can be defined as below: 
[ !! !,!(!!)!,!]!/! = [ !! !(!!)!]!/!  +[(!!)!(!!)!]!/! = (!)!(!!)! + (!)!(!!)!  
where 𝑓𝑎 !,! is the fraction of the population effect in combination of two 
drugs, (fa)1 and (fa)2 are fractions of affected cell population in presence of 
single drug D1 and D2, respectively. Based on the above equations Chou 
and Talalay in 1983 introduced the termed combination index (CI) for the 
evaluation of synergism or antagonism between two drugs as: 
𝐶𝐼 = (𝐷)!(𝐷!)! + (𝐷)!(𝐷!)! 
Where (𝐷!)!  and (𝐷!)!  are the doses of drug D1 and D2 to achieve a 
certain effect x, respectively. (𝐷)! & (𝐷)! are the doses of the drugs D1 and 
D2 in combination to achieve the same effect. CI < 1, = 1 and > 1 indicates 
synergism, additive effect and antagonism, respectively. The CI value can 
be categorized as follows: CI < 0.1 very strong synergism; 0.1-0.3 strong 
synergism; 0.3-0.7 synergism; 0.7-0.9 moderate/slight synergism; 0.9-1.1 
additive; 1.1-1.45 slight/moderate antagonism; 1.45-3.3 antagonism; 3.3-10 
strong antagonism; CI >10 very strong antagonism [81]. The dose 
reduction index is another important parameter that can be obtained from 
the median effect/CI model, which is defined as: 
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(𝐷𝑅𝐼)! = (𝐷!)!(𝐷)!  
The DRI value indicates how much of each drug in combination can be 
reduced, compared to the doses of each drug alone. CI and DRI values 
allow the quantitative determination of a synergistic effect between two 
drugs. This model will be used for our study of synergism between CDF 
and paclitaxel.  
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CDF concentration (µg/ml) Absorbance 
1 0.0946 
2 0.189 
3 0.284 
4 0.379 
5 0.474 
8 0.759 
10 0.949 
15 1.354 
20 1.775 
25 2.759 
Table 1: Standard graph of CDF in acetone by U.V spectrophotometry at 
wavelength 355 nm. (y = 0.117x – 0.3386 and R2 = 0.9454) 
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Paclitaxel concentration ((µg/ml) Area of elution peak 
0.5 26725 
1 47211 
5 234311 
10 213826 
20 437213 
50 1063001 
100 1932855 
200 3898352 
500 9610858 
1000 19116591 
Table 2: Standard graph of paclitaxel in acetonitrile by HPLC at wavelength 
225 nm. (y = 19067.1742x + 61071.8897 and R2 = 1) 
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CHAPTER 4: RESULTS AND DISCUSSION 
4.1 Characterization of conjugates 
            The schematic approach for the synthesis of CDF-PLGA-S-S-PEG 
was shown in figure 6 and 7. The synthetic procedure included 3 steps: (1) 
the preparation of the CDF-PLGA conjugate, which was prepared by the 
esterification between carboxyl-terminated PLGA and CDF in presence of 
DCC and DMAP (figure 6). (2) The disulfide PEG was synthesized by the 
reaction of PEG-thiol and cysteamine in methanol forming PEG-SS-NH2. 
An excess of unreacted cysteamine was removed by dialysis. (3) CDF-
PLGA-SS-PEG was prepared by the coupling reaction between the amino 
and carboxyl group of activated PLGA and PEG-SS-NH2 respectively 
(Figure 7).  
            The structures of the formed conjugates were verified with 1H NMR 
and FTIR. In the 1H NMR spectrum of the copolymer (figure not shown), 
four major peaks correspond to PLA (poly lactide), PGA (poly glycolide) 
and PEG segments appeared at 1.5 ppm (methyl of PLA) and 5.16 ppm 
(methine of PLA) and at 3.5 and 3.7 ppm (methylene of PEG) and at 4.8 
ppm (methylene of PGA) [78, 82]. CDF peaks were observed at 6.4, 6.7, 
7.1, 7.4 and 7.6 ppm.  
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             FTIR spectra were also used to confirm the formation of 
conjugates. As shown in figure 8, the typical C=O band at 1747 cm-1 in 
CDF-PLGA-S-S-PEG conjugate was appeared due to the presence of 
PLGA. The bands at 2865 cm-1 and 2857 cm-1 are ascribed to the 
asymmetric and symmetric CH2 stretching band of the PEG chains present 
in the CDF-PLGA-S-S-PEG conjugate. With TLC, a distinct spot for CDF 
and a band for CDF-PLGA conjugate was observed which indicate the 
formation of the conjugate. 
          The presence of these characteristic peaks relevant to CDF, PEG 
and PLGA supports the successful synthesis of the copolymer. Since this 
formed copolymer is amphiphilic as it has hydrophilic PEG attached to 
hydrophobic PLGA. Thus it will be able to form micelles with an outer PEG 
layer and inner PLGA core. Here PEG is attached to PLGA via a disulfide 
bond which we anticipate to be cleaved in elevated protease levels in tumor 
cells followed by hydrolysis of PLGA will release the drug from the micelles. 
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4.2 Physicochemical characterization of micelles 
4.2.1 Drug loading and encapsulation efficiency for micelles 
Formulation Wt% Drug 
loading 
% 
Encapsulation 
efficiency 
Size 
(nm) 
Zeta 
potential 
(mV) 
CDF-PLGA-SS-
PEG micelles 
0.4 8% 145 ±11 1.07±2.05 
PLGA-SS-PEG 
micelles 
encapsulating CDF 
8.9 89% 165±18.2 -0.43±3.21 
PLGA-SS-PEG 
micelles 
encapsulating 
Paclitaxel 
9.5 95% 171±17.4 0.89±1.45	  
PLGA-SS-PEG 
micelles 
coencapsulating 
CDF & Paclitaxel 
CDF-8.7% 
Paclitaxel-
9.1% 
CDF-87% 
Paclitaxel-91% 
208.5±21.3 1.12±2.38 
 
Table 3: Drug loading, encapsulation efficiency, size and zeta potential 
measurements of micelle formulations 
4.2.2 Micelle size and zeta potential 
            The size and zeta potential measurements are given in table 1 for 
all the micelle formulations. The zeta potential of all micelle formulations 
were about neutral. This helps in preventing the non-specific adsorption of 
proteins on to the surface of micelles and prevents the clearance from the 
monophagocytic system, which hinders the drug from reaching its targeting 
site [83]. The morphology of micelles was studied by AFM. The micelles 
were made initially with 1mg/ml of conjugate concentration and observed 
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micelle size was more than 300 nm (FIG 9). Then we reduced the 
concentration of the conjugate to make micelles with 100 µg/ml. The AFM 
images were taken and the size of micelles was well below 60 nm (FIG 10). 
The micelles were spherical. The micelle size was further confirmed by 
DLS measurements showed in Table 3. The micelle size is larger with DLS 
measurement which might be due to the presence of aggregates. The 
dehydration of micelles and the shrinkage of the PEG shell induced by 
water evaporation under high vacuum conditions before AFM observation 
led to smaller size measured by AFM. This smaller size prevents the 
uptake of micelles by the MPS and helps in penetrating the tumor by EPR 
effect. 
4.2.3 Critical micelle concentration (CMC) 
            Micelles were prepared by the dialysis method with the CDF-PLGA-
SS-PEG conjugate with increasing concentrations from 1 to 300 µg/ml. At a 
certain concentration the micelles are formed. That concentration is defined 
as critical micelle concentration (CMC).  
            The CMC value was determined using pyrene as a probe. The plot 
of fluorescence intensity ratio versus log concentration is shown in figure 
10. As indicated from the graph, the ratio of intensities is relatively constant 
until a certain point where there was an abrupt increase in this ratio. This 
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indicates the formation of micelles leading to the migration of pyrene into 
more hydrophobic PLGA core of the micelles. The CMC value was found to 
be 100 µg/ml. This low CMC value is an important feature in terms of drug 
delivery applications of micelles by providing them thermodynamic stability 
for in vivo use in a very dilute environment. 
4.2.4 In vitro drug release studies of micelles 
                In vitro drug release studies were carried out on CDF-PLGA-S-S-
PEG micelles coencapsulating both CDF and paclitaxel in presence and 
absence of GSH at various concentrations to get a release profile estimate 
of micelles within a reductive environment. The release of the drugs were 
studied at 20 µM GSH which is the concentration of GSH in plasma, 5 mM 
GSH which resembles the concentration of GSH in the cytosol and 
subcellular compartments and at 20 mM which is the concentration of GSH 
in tumor microenvironment [84, 85]. The release was also studied in 
presence of PBS (pH=7.4, 0.5% tween 80) without GSH. The release study 
with free CDF and paclitaxel was also done as a control in PBS. The 
results are shown in Figure 11. The release of CDF and paclitaxel from 
micelles was very slow in PBS without GSH. Only 4.6% CDF and 3% 
paclitaxel were released in the first 4 h in just PBS without any GSH. 
Whereas 4.8%, 4.9% and 24% of CDF and 4.9%, 10.26% and 21.7% 
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paclitaxel were released in 20 µM, 5mM and 20 mM GSH respectively. So 
at highest GSH concentration i.e. at 20 mM GSH the drug release was 
fastest because of the increased cleavage of disulfide bond thereby 
shedding the PEG coating followed by hydrolysis of PLGA which further 
releases the encapsulated drug by diffusion.   
              Within 24 h 55% of CDF and 52.6% paclitaxel were released in 20 
mM GSH which is much higher when compared to the release in presence 
of 20 µM and 5mM GSH. This indicates that the drug is released from 
micelles fast only when it is exposed to a highly reductive environment. In 
plasma and cytosol, where the GSH concentration is low, the drug release 
is much slower. This indicates that the micelles will not release any drug in 
those areas as the disulfide bond cannot be cleaved at these low GSH 
levels. The release of drugs from micelles without redox sensitivity was 
even slower in the absence of GSH or at 20 µM GSH. Around 80% of the 
drug was released in 72 h at 20 mM GSH concentration. 
         Based on our results we have shown that a certain degree of disulfide 
bond breakage was necessary to release CDF and paclitaxel from the inner 
core of micelles, which is higher in tumor cells because of high GSH 
concentrations. These micelles are likely to be stable in plasma on 
exposure to low GSH concentration (20 µM) and even at cytosolic GSH 
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concentration (5 mM) the drug release was slow indicating the micelles 
would remain intact when intravenously administered, and rapidly release 
the drug in the tumor microenvironment. Therefore, PLGA-SS-PEG 
micelles coencapsulating CDF and paclitaxel can be a highly promising 
drug delivery system to achieve intracellular fast release of anticancer 
drugs and enhance their therapeutic efficacy. 
4.2.5 Cell culture studies 
4.2.5.1 Invitro cytotoxicity studies 
              The cytotoxicity effect of free CDF, free Paclitaxel, CDF micelles, 
paclitaxel micelles and micelles coencapsulating CDF & paclitaxel were 
evaluated on BXPC-3 (pancreatic cancer) and SKOV-3 (ovarian cancer) 
cells at the end of 24, 48 and 72 hours of incubation. The IC50 values for 
each formulation on BXPC-3 cells and SKOV-3 cells are represented in 
table 4 and table 5 respectively. 
           The results of the cytotoxicity experiment on BXPC-3 cells with CDF 
micelles, paclitaxel micelles, micelles coencapsulating both CDF and 
paclitaxel micelles and control micelles were shown in figure 12, 13, 14 
and 15 respectively. The results of the cytotoxicity experiment on SKOV-3 
cells with CDF micelles, paclitaxel micelles, micelles coencapsulating both 
CDF and paclitaxel micelles and control micelles were shown in figure 16, 
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17, 18 and 19 respectively. The control micelles used were CDF-PLGA-
SS-PEG micelles without any encapsulated drug as these micelles had 
only 0.4% CDF loading. This didnot have any antiproliferative effect at the 
dilutions of different concentrations of CDF and Paclitaxel used for the MTT 
assay. So it was used as control and the same conjugate was used to 
prepare micelles encapsulating CDF, paclitaxel and both CDF and 
paclitaxel. The control micelles were tested at the same dilutions as CDF 
micelles. 
            A time and concentration dependent antiproliferative effect was 
displayed with all the formulations in both cell lines. As the concentration of 
the drug and exposure time increases, the anti proliferative effect is 
increased. At the 72 h time point, in both cell lines, maximum cell death 
was observed and it was much higher with the micelles coencapsulating 
CDF and paclitaxel. The IC50 values were less with micelles than free drug 
for both cell lines at the 72h time point.  
          Figure 12 and 15 represents the % cell viability of BXPC-3 cells and 
SKOV-3 cells upon incubation with several concentrations of free CDF and 
CDF micelles at 24 h, 48 h and 72 h time points. At the 24 h time point for 
BXPC-3 cells, free CDF was more effective than micelles. At 48 and 72 h 
time points CDF micelles are as effective as free drug. There is a 
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concentration dependent antiproliferative effect displayed both by free CDF 
and CDF micelles in both cell lines. The IC50 values were significantly 
lowered at 72 h time point in BXPC-3 and SKOV-3 cells indicating a time 
dependent antiproliferative effect of free CDF and CDF loaded micelles. 
The IC50 value was 2.4 µM for free CDF and 2.1 µM for CDF loaded 
micelles in BXPC3 cells and 16.37 µM for free CDF and 14.7 µM for CDF 
loaded micelles which indicated micelles are as efficient as free drug. 
Formulating CDF into micelles did not hamper its anti proliferative effect. 
We anticipate that these micelles are advantageous when we administer 
the drug in vivo in which case these micelles can remain intact until 
exposed to a highly reductive environment suchas tumor cells (20 mM 
GSH) as it was shown in the drug release studies and cytotoxic effect of 
free drug on normal cells can be reduced. 
              Figure 13 and 16 represents the % cell viability of BXPC3 and 
SKOV3 cell respectively upon incubation with several concentrations of 
free paclitaxel and paclitaxel loaded micelles at 24 h, 48 h and 72 h time 
points. From figure 13, for BXPC3 cells the IC50 value for paclitaxel was 
527 nM at 24 h, 45.82 nM at 48 h and 10.4 nM at 72 h time points. The 
reason for this significant difference might be due to the mechanism of 
action of paclitaxel, which is a mitotic inhibitor and cell cycle specific. So 
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until the 24 h time point the cells are not in active proliferative stage and so 
the effect of paclitaxel was not significant at this time when compared to 48 
h and 72 h where paclitaxel actually started showing its anti proliferative 
effects on BXPC-3 cells. At all time points paclitaxel loaded micelles are as 
effective as free paclitaxel. At the 48 h time point micelles have shown 
more anti proliferative effect when compared to free drug at all 
concentrations for BXPC-3 cells. From figure 16, for SKOV-3 cells which 
are resistant to paclitaxel there was very less difference in IC50 values at 
various time points. The IC 50 was 11.32 µM for free paclitaxel at 24 h and 
8.22 µM at 72 h time point. At all time points the IC50 values for paclitaxel 
loaded micelles were lower than free drug. In SKOV-3 cells a high amount 
of paclitaxel is required to produce cytotoxicity.  
          Figure 14 and 17 represent the % cell viability of BXPC-3 and 
SKOV-3 cells respectively when a combination of CDF and paclitaxel was 
used as free drugs and also coencapsulated in micelles and tested at the 
end of 24 h, 48 h and 72 h. BXPC-3 is sensitive cell line to both CDF and 
paclitaxel. From figure 14, on BXPC-3 cells the antiproliferative effect is 
significantly increased for the drug combination for free drugs as well as in 
micelles at all time points and all the concentrations tested. Except for the 
24 h time point from table 1, IC50 values were less for the micelle 
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formulation than for the free drug. At 24 h the release of drug from micelles 
might be less so less drug is available when compared to free drug. The 
IC50 values significantly decreased in combination from 2.4 µM to 0.1 µM 
of CDF and 10.4 nM to 7.5 nM paclitaxel at 72 h. From figure 17, on 
SKOV-3 cells the combination of CDF and paclitaxel has shown very 
significant anti proliferative effect when compared to that of CDF and 
paclitaxel alone. The micelles encapsulating both CDF and paclitaxel have 
shown very similar antiproliferative effect when compared to the 
combination of both free drugs except at 24 h. SKOV-3 cells are much 
more sensitive to the combination when compared to individual drugs. 
From table 2 the IC50 value is 16.37 µM for CDF and 8.22 µM for 
paclitaxel whereas in combination it was 9.8 µM for CDF and 1.56 µM for 
paclitaxel at 72 h.  
        Based on cell viability study results we assume that PLGA-SS-PEG 
micelles incorporating CDF, paclitaxel and both of those are as effective as 
free drugs during MTT assay. We believe based on these results as well as 
from the drug release study results that CDF and paclitaxel when 
incorporated into micelles will work more efficiently than the free drug form 
in vivo. The hydrophilic PEG layer of micelles make them circulate for 
longer period in the body and thus it provides more chance to release the 
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drug in tumor when exposed to high glutathione levels of tumor cells (20 
mM). Even though there is glutathione present in the cytoplasm its 
concentration is much lower (5mM) when compared to tumor cells so the 
degradation of micelles is less likely in those regions. Similar is the case 
with plasma where the GSH concentration is 20 µM to which the disulfide 
bond in micelles is not susceptible. Because of the enhanced permeation 
and retention effect in tumor cells and size of our micelles which is less 
than 200 nm, and PEG coating it is more likely that micelles will penetrate 
tumor cells more effciently and then by reduction of the disulfide bond 
within the tumor cells they will release the drug internally. Therefore the 
overall cytotoxicity to the normal cells can be reduced with this formulation.  
4.2.5.2 Evaluation of combination effect of CDF and paclitaxel in           
micelles 
              In order to test the chemo sensitizing ability of CDF we chose 
paclitaxel as the model drug. We tested the synergistic effect of CDF and 
paclitaxel against BXPC-3 and SKOV-3 cells. The combination index 
values are given in table 6 and 7 for SKOV-3 and BXPC-3 cells 
respectively.  
             The SKOV-3 cell line used is a model for paclitaxel resistance as 
	  	  
54	  
very high concentration of drug is required to obtain get 50 % cell killing 
(IC50 8.2 µM). Acoordingly we used micelles coencapsulating CDF and 
paclitaxel and CDF micelles and paclitaxel micelles to test the synergy. 
From the combination index values given in table 6 for SKOV-3 cells, the 
free drug combination at 24 h has a combination index (CI) value equal to 
1, indicating the additive effect at that point. The degree of synergy 
increased as the exposure time of the drug to the SKOV-3 cells increased 
showing maximum synergy at the 72 h time point. The synergy between 
CDF and paclitaxel further increased by coencapsulating both drugs in the 
micelle formulation in which CI was 0.62. the CI for free drug combination 
was 0.66. By coencapsulating the two drugs in one micelle formulation, 
when used in vivo it is possible for both the drugs to reach and penetrate 
the tumor cell at the same time and release the drug inside the tumor to 
complement each other inside the cell to produce a maximum synergistic 
effect. When used in combination in micelles, the IC50 values for both CDF 
and paclitaxel were reduced from 14.7 µM and 7.9 µM to 8.2 µM and 1.48 
µM respectively. P-gp is the major protein involved for MDR against 
taxanes. This is a membrane bound protein and acts as efflux pump for 
drugs and so the drugs cannot achieve the required concentration to 
produce a cytotoxic effect. Curcumin was found to down regulate these 
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ABC transporters and thereby it can increase the sensitivity of cells 
otherwise resistant paclitaxel.  
            Similarly from table 7, combination effect values against BXPC-3 
cells also indicate synergy between CDF and SKOV-3 cells. Since CDF 
has multiple effects such as inhibiting NF- ΚB, EGFR, HER2, STAT-3 and 
also inhibits ABC transporters. Because of this ability of CDF to effect 
different molecular mechanisms of cancer it causes apoptosis of cancer 
cells, whereas paclitaxel being a mitotic inhibitor acts on cell cycle and 
inhibits the formation of new cells. So when they are used in combination, 
synergy is produced by effecting cancer cell growth during cell division and 
by causing apoptosis at the same time thereby increasing the effectiveness 
of therapy.  
              Dose reduction index values (DRI) are calculated and given in 
table 8 for SKOV-3 and BXPC-3 cells to estimate the reduction of the 
overall dose when coencapsulated together in micelles compared to CDF 
micelles and paclitaxel micelles to produce 50 % cell killing at the 72 h time 
point where maximum synergy was observed. In case of SKOV-3 cells 
there was a 5.3 fold reduction in paclitaxel and a 1.8 fold reduction in CDF 
concentration was observed. For BXPC-3 cells, a 16 fold reduction in CDF 
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and a 1.5 fold reduction in paclitaxel was observed. In SKOV-3 cells which 
requires a high concentration of paclitaxel, micelles coencapsulating CDF 
and paclitaxel will be advantageous to reduce the overall dose of paclitaxel 
when combined with CDF to reduce the overall toxicity associated with 
using high amounts of paclitaxel. Based on these results we concluded that 
the combination of CDF and paclitaxel in micelles formulation will help to 
reduce the dose of the individual drugs in combination therapy and thereby 
less drug is sufficient to produce cytotoxic effect to cancer cells. Combining 
different drugs in one formulation is advantageous mainly in MDR cancers. 
The drug combination will also helps in reducing the lethal side effects 
caused by cancer chemo therapeutics as the overall dose can be reduced. 
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FIGURE 8: FTIR spectra of synthesized conjugates 
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 Figure 9: AFM images of CDF-PLGA-SS-PEG micelles with conjugate 
concentration of 1 mg/ml. 
 
Figure 10: AFM images of CDF-PLGA-SS-PEG micelles with conjugate 
concentration of 100 µg/ml. 
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Figure 10: CMC for PLGA-SS-PEG micelles using pyrene as a 
fluorescence probe. 
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Figure 11: Invitro drug release studies of micelle coencapsulating CDF and 
paclitaxel in PBS and PBS containing 20 µM, 20 mM and 5 mM GSH. 
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Figure 12: Percentage Cell viability of BXPC3 cells upon incubation with 
free CDF and micelles encapsulating CDF at the end of 24 h, 48 h and 72 
h; *, p<0.05 between drug and micelles (n=8; mean ± S.D)	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Figure 13: Percentage Cell viability of BXPC3 cells upon incubation with 
free Paclitaxel and micelles encapsulating Paclitaxel at the end of 24 h, 48 
h and 72 h; *, p<0.05 between drug and micelles (n=8; mean ± S.D)	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Figure 14: Percentage Cell Cell viability of BXPC3 cells upon incubation 
with free CDF and Paclitaxel and micelles encapsulating both CDF & 
Paclitaxel at the end of 24 h, 48 h and 72 h; *, p<0.05 between drug and 
micelles (n=8; mean ± S.D)	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Figure 15: Percentage Cell Cell viability of BXPC3 cells upon incubation 
with control micelles at the same dilutions as micelles with drug at the end 
of 24 h, 48 h and 72 h. (n=8; mean ± S.D)	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Figure 16: Percentage Cell Cell viability of SKOV3 cells upon incubation 
with free CDF and micelles encapsulating CDF at the end of 24 h, 48 h and 
72 h; *, p<0.05 between drug and micelles (n=8; mean ± S.D)	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Figure 17: Percentage Cell Cell viability of SKOV3 cells upon incubation 
with free Paclitaxel and micelles encapsulating Paclitaxel at the end of 24 
h, 48 h and 72 h; *, p<0.05 between drug and micelles (n=8; mean ± S.D)	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0	  10	  
20	  30	  
40	  50	  
60	  70	  
80	  90	  
100	  
5	   4	   3	   2	   1	   0.75	   0.5	   0.25	   0.1	  
%
	  C
el
l	  v
ia
bi
lit
y	  
Paclitaxel	  (μM)	  
ptx	  24	  hr	  ptx	  micelles	  24	  hr	  ptx	  48	  hr	  ptx	  micelles	  48hr	  ptx	  72	  hr	  ptx	  micelles	  72	  hr	  
	  	  	  *	   	  	  	  	  	  *	   	  *	  	  	  	  *	   	  	  	  	  	  *	  	  	  	   	  *	   	  *	  
	  *	  	  	  	  	  *	   	  	  	  *	  
	  
	  	  
67	  
 
Figure 18: Percentage Cell Cell viability of SKOV3 cells upon incubation 
with free CDF and paclitaxel and micelles encapsulating both CDF & 
Paclitaxel at the end of 24 h, 48 h and 72 h; *, p<0.05 between drug and 
micelles (n=8; mean ± S.D)	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Figure 19: Percentage Cell Cell viability of SKOV3 cells upon incubation 
with control micelles at the same dilutions as micelles with drug at the end 
of 24 h, 48 h and 72 h. (n=8; mean ± S.D)	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Time 
(Hours) 
Free 
CDF 
(µM) 
Free 
Paclitaxel 
(nM) 
Free CDF & 
Paclitaxel 
(µM & nM) 
 
PLGA-SS-PEG 
micelles 
encapsulating 
CDF (µM) 
PLGA-SS-PEG 
micelles 
encapsulating 
Paclitaxel (nM) 
PLGA-SS-PEG 
micelles 
coencapsulating 
CDF & Paclitaxel 
(µM & nM) 
 
24 12.9 527 4.8 & 281.5 15.3 610.4 5.3 & 308 
48 5.9 45.82 0.79 & 
34.54 
6.76 33.46 0.48 & 28.3 
72 2.4 10.4 0.15 & 7.5 2.1 9.82 0.13& 6.4 
Table 4: IC50 values of CDF and paclitaxel alone and in combination on 
BXPC3 cells, in the free drug form and micelle formulation 
Time 
(Hours) 
Free 
CDF 
(µM) 
Free 
Paclitaxel 
(µM) 
Free CDF & 
free 
Paclitaxel 
(µM & µM) 
 
PLGA-SS-PEG 
micelles 
encapsulating 
CDF (µM) 
PLGA-SS-PEG 
micelles 
encapsulating 
Paclitaxel (µM) 
PLGA-SS-PEG 
micelles 
coencapsulating 
CDF & Paclitaxel 
(µM & µM) 
 
24 51.3 11.32 42.12 & 
3.44 
49.68 10.78 39.2 & 3.27 
48 29.44 10.59 19.48 & 
2.12 
29.79 10.15 18.68 & 2.09 
72 16.37 8.22 9.8 &1.56 14.7 7.9 8.2 & 1.48 
Table 5: IC50 values of CDF and paclitaxel alone and in combination on 
SKOV3 cells, in the free drug form and micelle formulation 
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Time points 
(Hours) 
Free drug 
combination 
Micelles 
formulations 
24 1 0.99 
48 0.7 0.65 
72 0.66 0.62 
 
Table 6: CDF and paclitaxel combination index (CI) against SKOV3 cells 
CI < 1, synergistic; CI = 1, additive; CI > 1, antagonistic. 
 
 
 
 
Time points 
(Hours) 
Free drug 
combination 
Micelles 
formulations 
24 0.9 0.85 
48 0.88 0.87 
72 0.77 0.7 
 
Table 7: CDF and paclitaxel combination index (CI) against BXPC3 cells 
CI < 1, synergistic; CI = 1, additive; CI > 1, antagonistic. 
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Drug BXPC 3 SKOV 3 
CDF 16 1.7 
Paclitaxel 1.5 5.3 
 
Table 8: Dose reduction index (DRI) values for CDF and paclitaxel with 
micelles coencapsulating both CDF and paclitaxel when compared to CDF 
micelles and paclitaxel micelles in BXPC3 and SKOV3 cell lines at 72 h 
time point. 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
        The design, synthesis, characterization and invitro evaluation of CDF-
PLGA-S-S-PEG micelles encapsulating CDF, paclitaxel and both were 
investigated here are representation of nanocarriers which have the ability 
to improve the solubility of the free drug. Favorable size distribution, very 
low CMC, good biocompatibility of prepared micelles proved their greater 
potential for delivering anti cancer drugs via intravenous injection in the 
cancer treatment. The prepared copolymer has self-assembled properties 
which was confirmed by its low CMC (100 µg/ml). The nanomicelles were 
successfully prepared with drug loading capacity of around 9% for all the 
formulations. But the conjugated CDF loading was very less 0.4%. The 
prepared conjugate was successful in encapsulating CDF and paclitaxel 
individually and also as combined formulation. The drug release studies 
proved that these micelles displayed low drug release under non-reductive 
environment while releasing the drug rapidly and quantitatively in presence 
varying concentrations of reducing agent GSH.  
             In both the cell lines there was a clear time and concentration 
dependent cell growth inhibition was observed. In case of SKOV3 and 
BXPC3 cell lines, the IC50 values were very close to free drug indicating 
the encapsulation of free drugs in to micelles did not hamper their 
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therapeutic properties. The micelles encapsulating both CDF and paclitaxel 
were found to be much more efficient than when individual drugs were 
incorporated in both the cell lines. The IC50 of both the drugs reduced 
when used in combination and CDF proved to sensitize the SKOV3 cells to 
paclitaxel therapy.  
            The present study indicates that the co-delivery system provides a 
promising platform for cancer therapy as the combination treatment is 
much efficient in multi drug resistant cancers. Since the IC50 of drugs can 
be reduced when used in combination, the overall side effects of these 
drugs can be reduced by decreasing the dose of the drug given to the 
patient. By using PLGA-S-S-PEG micelles, it is possible to incorporate 
multiple drugs in one formulation along with smaller size of micelles, 
disulfide bond which can breakdown only in presence of highly reductive 
environment like tumor cells and PEG outer layer which prevents the 
uptake by MPS system, these micelles can circulate longer time in plasma 
and because of EPR effect they can successfully reach tumor cells without 
releasing the drug any where else in the body. 
          In summary, our work of fabricating polymeric micelles 
coencapsulating two drugs has significant implications in treatment of 
various multi drug resistant cancers. This body of work provides a platform 
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for developing micelle systems with different drugs to treat various cancers. 
Specifically, results from this work will be used in the future to investigate 
the synergistic therapeutic effect in pancreatic and ovarian cancer mice 
model. Finally, based on the knowledge gained from all my work, polymeric 
micelles could provide a platform for an effective drug delivery system 
which can be passively and actively target the tumor site along with multi 
drug delivery to the tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
75	  
REFERENCES 1.	   Clifford	   J.	  Whatcott,	   R.G.P.,	  Daniel	  D.	   Von	  Hoff,	   and	  Haiyong	  Han,	  Desmoplasia	  and	  
chemoresistance	   in	   pancreatic	   cancer.	   Pancreatic	   cancer	   and	   tumor	  microenvironment.	  2012:	  Transworld	  Research	  Network.	  2.	   Szakács	   G,	   P.J.,	   Ludwig	   JA,	   Booth-­‐Genthe	   C,	   Gottesman	   MM,	   Targeting	   multidrug	  
resistance	  in	  cancer.	  Nat	  Rev	  Drug	  Discov,	  2006.	  5(3):	  p.	  219-­‐234.	  3.	   Jemal,	  A.,	  et	  al.,	  Cancer	  statistics,	  2009.	  CA	  Cancer	  J	  Clin,	  2009.	  59(4):	  p.	  225-­‐49.	  4.	   http://training.seer.cancer.gov/disease/cancer/,	   SEER	  Training	  Modules,	   Cancer	   as	  
a	  disease.	  U.	  S.	  National	  Institutes	  of	  Health,	  National	  Cancer	  Institute.,	  01/05/2014.	  5.	   <Cell	  Biology	  and	  Cancer.pdf>.	  6.	   world	  cancer	  report	  2008.	  7.	   Ghaneh,	  P.,	  E.	  Costello,	  and	  J.P.	  Neoptolemos,	  Biology	  and	  management	  of	  pancreatic	  
cancer.	  Postgraduate	  Medical	  Journal,	  2008.	  84(995):	  p.	  478-­‐497.	  8.	   Pandol,	   S.,	   et	   al.,	   Desmoplasia	   of	   pancreatic	   ductal	   adenocarcinoma.	   Clin	  Gastroenterol	  Hepatol,	  2009.	  7(11	  Suppl):	  p.	  S44-­‐7.	  9.	   Shimizu,	   K.,	  Mechanisms	   of	   pancreatic	   fibrosis	   and	   applications	   to	   the	   treatment	   of	  
chronic	  pancreatitis.	  Journal	  of	  Gastroenterology,	  2008.	  43(11):	  p.	  823-­‐832.	  10.	   loos,	  M.,	  et	  al,	  Surgical	  treatment	  of	  pancreatic	  cancer.	  Ann	  N	  Y	  Acad	  Sci,	  2008(1138):	  p.	  169-­‐180.	  11.	   Wagner,	  M.,	   et	  al,	  Curative	  resection	  is	  the	  single	  most	  important	  factor	  determining	  
outcome	   in	   patients	   with	   pancreatic	   adenocarcinoma.	   British	   Journal	   of	   Surgery,	  2004.	  91(5):	  p.	  586-­‐594.	  
	  	  
76	  
12.	   Zalatnai,	   A.a.J.M.,	   Review.	   Molecular	   background	   of	   chemoresistance	   in	   pancreatic	  
cancer.	  In	  vivo.	  2007.	  21(3):	  p.	  339-­‐347.	  13.	   Kim,	  M.P.a.G.E.G.,	  Gemcitabine	  resistance	  in	  pancreatic	  cancer:	  picking	  the	  key	  players.	  clinical	  cancer	  research,	  2007.	  14(5):	  p.	  1284-­‐1285.	  14.	   sakai,	  W.,	  et	  al,	  Secondary	  mutations	  as	  a	  mechanism	  of	  cisplatin	  resistance	  in	  BRCA2-­‐
mutated	  cancers.	  nature,	  2008.	  451(7182):	  p.	  1116-­‐1120.	  15.	   B,	  B.,	  plants	  consumed	  by	  man.	  newyork,	  acdemic	  press	  ,	  1975:	  p.	  331.	  16.	   Goel,	   A.	   and	   B.B.	   Aggarwal,	   Curcumin,	   the	   golden	   spice	   from	   Indian	   saffron,	   is	   a	  
chemosensitizer	   and	   radiosensitizer	   for	   tumors	   and	   chemoprotector	   and	  
radioprotector	  for	  normal	  organs.	  Nutr	  Cancer,	  2010.	  62(7):	  p.	  919-­‐30.	  17.	   Sharma,	  R.A.,	  A.J.	  Gescher,	  and	  W.P.	  Steward,	  Curcumin:	  the	  story	  so	  far.	  Eur	  J	  Cancer,	  2005.	  41(13):	  p.	  1955-­‐68.	  18.	   Teiten,	  M.H.,	  et	  al.,	  Curcumin-­‐the	  paradigm	  of	  a	  multi-­‐target	  natural	  compound	  with	  
applications	  in	  cancer	  prevention	  and	  treatment.	  Toxins	  (Basel),	  2010.	  2(1):	  p.	  128-­‐62.	  19.	   Lin,	   j.-­‐K.,	  Molecular	  targets	  of	  curcumin.	   ADVANCES	   IN	  EXPERIMENTAL	  MEDICINE	  AND	  BIOLOGY	  2007.	  595:	  p.	  227-­‐243.	  20.	   H,	  B.I.a.O.,	  Curcumin,	  an	  anti-­‐tumour	  promoter	  and	  anti-­‐	  inflammatory	  agent,	  inhibits	  
induction	   of	   nitric	   oxide	   synthase	   in	   activated	   macrophages.	   biochemical	   and	  biophysical	  research	  communications,	  1995.	  206:	  p.	  533-­‐540.	  21.	   MN,	   S.x.R.,	   Nitric	   oxide	   scavenging	   by	   curcuminoids.	   journal	   of	   pharmacy	   and	  pharmacology,	  1997.	  49:	  p.	  105-­‐107.	  
	  	  
77	  
22.	   MR,	  D.C.a.P.,	  Antitumor	  action	  of	  curcumin	  in	  human	  pa-­‐	  pillomavirus	  associated	  cells	  
involves	   downregulation	   of	   viral	   oncogenes,	   prevention	   of	   NFkB	   and	   AP-­‐1	  
translocation,	   and	  modulation	   of	   apoptosis.	   molecular	   carcinogenesis,	   2006.	  45:	   p.	  320-­‐332.	  23.	   Kiso	   Y	   ,	   S.Y.,	   Watanabe	   N,	   Oshima	   Y	   ,	   and	   Hikino	   H,	   Antihepatotoxic	   principles	   of	  
Curcuma	  longa	  rhizomes.	  planta	  medica,	  1983.	  49:	  p.	  185-­‐187.	  24.	   Srivastava	  R,	   D.M.,	   Srimal	   RC,	   and	  Dhawan	  BN,	  Anti-­‐thrombotic	  effect	  of	   curcumin.	  thrombosis	  research,	  1985.	  40:	  p.	  413-­‐417.	  25.	   N,	  V.,	  Curcumin	  attenuation	  of	  acute	  adriamycin	  myocardial	  toxi-­‐	  city	  in	  rats.	  british	  journal	  of	  pharmacology,	  1998.	  124:	  p.	  425-­‐427.	  26.	   Deodhar	   SD,	   S.R.,	   and	   Srimal	   RC,	   Preliminary	   study	   on	   antirheumatic	   activity	   of	  
curcumin	  (diferuloyl	  methane).	  Indian	  journal	  of	  medical	  research,	  1980.	  71:	  p.	  631-­‐634.	  27.	   Chan	  MM,	  A.N.,	  and	  Fong	  D,	  Curcumin	  overcomes	  the	  inhibitory	  effect	  of	  nitric	  oxide	  
on	  Leishmania.	  Parasitology	  research,	  2005.	  96:	  p.	  49-­‐56.	  28.	   Cheng	   AL,	   H.C.,	   Lin	   JK,	   et	   al,	   Phase	   I	   clinical	   trial	   of	   curcumin,	   a	   chemopreventive	  
agent,	  in	  patients	  with	  high-­‐risk	  or	  pre-­‐malignant	  lesions.	  Anticancer	  research,	  2001.	  
21:	  p.	  2895-­‐2900.	  29.	   Aggarwal	   BB,	   K.A.,	   Bharti	   AC,	   Anticancer	   potential	   of	   curcumin:	   preclinical	   and	  
clinical	  studies.	  Anticancer	  research,	  2003.	  23:	  p.	  363-­‐398.	  30.	   Rajesh	   L.	   Thangapazham,	   A.S.a.R.K.M.,	   Multiple	   molecuar	   targets	   in	   cancer	  
chemoprevention	  by	  curcumin.	  The	  AAPS	  Journal,	  2006.	  8(3).	  
	  	  
78	  
31.	   Fazlul	  H.	  Sarkar,	  Q.P.D.,	  Subhash	  Padhye,	  Novel	  analogs	  of	  curcumin	  and	  methods	  of	  
use.	  2011.	  32.	   Jutooru,	  I.,	  et	  al.,	  Inhibition	  of	  NFkappaB	  and	  pancreatic	  cancer	  cell	  and	  tumor	  growth	  
by	  curcumin	  is	  dependent	  on	  specificity	  protein	  down-­‐regulation.	   J	  Biol	  Chem,	  2010.	  
285(33):	  p.	  25332-­‐44.	  33.	   Holcomb	  B,	  Y.-­‐S.M.,	  Matos	  JM,	  Dixon	  J,	  Kennard	  J,	  et	  al,	  Pancreatic	  cancer	  cell	  genetics	  
and	   signaling	   response	   to	   treatment	   corre-­‐	   late	   with	   efficacy	   of	   gemcitabine-­‐based	  
molecular	  targeting	  strategies.	  J	  Gastrointest	  Surg	  2008.	  12:	  p.	  288-­‐296.	  34.	   Hour	   TC,	   C.J.,	   Huang	   CY,	   Guan	   JY,	   Lu	   SH,	   et	   al,	   Curcumin	   enhances	   cytotoxicity	   of	  
chemotherapeutic	   agents	   in	   prostate	   cancer	   cells	   by	   inducing	   p21(WAF1/CIP1)	   and	  
C/EBPbeta	  expressions	  and	  suppressing	  NF-­‐kappaB	  activation.	  Prostate,	  2002.	  51:	  p.	  211-­‐218.	  35.	   Chan	  MM,	  F.D.,	   Soprano	  KJ,	  Holmes	  WF,	   and	  Heverling	  H,	   Inhibition	  of	  growth	  and	  
sensitization	   to	   cisplatin-­‐mediated	   killing	   of	   ovarian	   cancer	   cells	   by	   polyphenolic	  
chemopreventive	  agents.	  J	  Cell	  Physiol,	  2003.	  194:	  p.	  63-­‐70.	  36.	   Navneet	   Dhillon,	   B.B.A.,	   Robert	   A.	   Newman,	   et	   al,	   Phase	   II	   Trial	   of	   Curcumin	   in	  
Patients	  with	  Advanced	  Pancreatic	  Cancer.	  Clin	  Cancer	  Res	  2008.	  14:	  p.	  4491-­‐4499.	  37.	   Takahashi,	   M.,	   et	   al,	   Characterization	   and	   bioavailability	   of	   liposomes	   containing	   a	  
ukon	  extract.	  Biosci	  Biotechnol	  Biochem,	  2008.	  72(5):	  p.	  1199-­‐1205.	  38.	   Maiti,	   K.,	   et	   al,	  Curcumin-­‐phospholipid	  complex:	  Preparation,	   therapeutic	  evaluation	  
and	  pharmacokinetic	  study	  in	  rats.	  Int	  J	  Pharm,	  2007.	  330(1-­‐2):	  p.	  155-­‐163.	  
	  	  
79	  
39.	   Ma,	   Z.,	   et	   al,	   High-­‐performance	   liquid	   chromatography	   analysis	   of	   curcumin	   in	   rat	  
plasma:	   application	   to	   pharmacokinetics	   of	   polymeric	   micellar	   formulation	   of	  
curcumin.	  Biomed	  Chromatogr,	  2007.	  21(5):	  p.	  546-­‐552.	  40.	   Bisht,	   S.,	   et	   al,	   Polymeric	   nanoparticle-­‐encapsulated	   curcumin	   ("nanocurcumin"):	   a	  
novel	  strategy	  for	  human	  cancer	  therapy.	  J	  Nanobiotechnology,	  2007.	  5:	  p.	  3.	  41.	   Anand,	   P.,	   et	   al,	   Design	   of	   curcumin-­‐loaded	   PLGA	   nanoparticles	   formulation	   with	  
enhanced	   cellular	   uptake,	   and	   increased	   bioactivity	   in	   vitro	   and	   superior	  
bioavailability	  in	  vivo.	  Biochem	  Pharmacol,	  2010.	  79(3):	  p.	  330-­‐338.	  42.	   Yallapu,	  M.M.,	  M.	   Jaggi,	   and	   S.C.	   Chauhan,	  beta-­‐Cyclodextrin-­‐curcumin	   self-­‐assembly	  
enhances	   curcumin	   delivery	   in	   prostate	   cancer	   cells.	   Colloids	   Surf	   B	   Biointerfaces.	  
79(1):	  p.	  113-­‐125.	  43.	   Shahani,	   K.,	   et	   al,	   Injectable	   sustained	   release	   microparticles	   of	   curcumin:	   a	   new	  
concept	  for	  cancer	  chemoprevention.	  Cancer	  Res,	  2010.	  70(11):	  p.	  4443-­‐4452.	  44.	   Gou,	   M.,	   et	   al.,	   Curcumin-­‐loaded	   biodegradable	   polymeric	  micelles	   for	   colon	   cancer	  
therapy	  in	  vitro	  and	  in	  vivo.	  Nanoscale,	  2011.	  3(4):	  p.	  1558-­‐67.	  45.	   Yallapu,	   M.M.,	   et	   al,	   Fabrication	   of	   curcumin	   encapsulated	   PLGA	   nanoparticles	   for	  
improved	   therapeutic	   effects	   in	   metastatic	   cancer	   cells.	   Journal	   of	   Colloid	   and	  Interfacial	  Science,	  2010.	  351(1):	  p.	  19-­‐29.	  46.	   Shaikh,	  J.,	  et	  al,	  Nanoparticle	  encapsulation	  improves	  oral	  bioavailability	  of	  curcumin	  
by	   at	   least	   9-­‐fold	   when	   compared	   to	   curcumin	   administered	   with	   piperine	   as	  
absorption	  enhancer.	  Eur	  J	  Pharm	  Sci,	  2009.	  37(3-­‐4):	  p.	  223-­‐230.	  47.	   Zambare	   AP,	   J.A.,	   Padhye	   S,	   Kulkarni	   VM,	   Copper	   conjugates	   of	   Knoevenagel	  
condesates	   of	   Curcumin	   and	   their	   Schiff	   base	   derivatives:	   synthesis,	   spectroscopy,	  
	  	  
80	  
magnetism,	  EPR	  and	  electrochemistry.	  Synth	  React	   Inorg,	  Metal-­‐Org	  and	  NanoMetal	  Chemistry,	  2007.	  37(19-­‐27).	  48.	   Padhye,	   S.,	   et	   al.,	   New	   difluoro	   Knoevenagel	   condensates	   of	   curcumin,	   their	   Schiff	  
bases	  and	  copper	  complexes	  as	  proteasome	  inhibitors	  and	  apoptosis	  inducers	  in	  cancer	  
cells.	  Pharm	  Res,	  2009.	  26(8):	  p.	  1874-­‐80.	  49.	   Padhye,	   S.,	   et	   al.,	  Fluorocurcumins	  as	  cyclooxygenase-­‐2	  inhibitor:	  molecular	  docking,	  
pharmacokinetics	  and	  tissue	  distribution	  in	  mice.	  Pharm	  Res,	  2009.	  26(11):	  p.	  2438-­‐45.	  50.	   Ali,	  S.,	  et	  al.,	  Gemcitabine	  sensitivity	  can	  be	  induced	  in	  pancreatic	  cancer	  cells	  through	  
modulation	   of	   miR-­‐200	   and	   miR-­‐21	   expression	   by	   curcumin	   or	   its	   analogue	   CDF.	  Cancer	  Res,	  2010.	  70(9):	  p.	  3606-­‐17.	  51.	   Bin	  Bao,	  S.A.,	  Dejuan	  Kong,	  Sanila	  H.	  Sarkar,	  Zhiwei	  Wang,	  Sanjeev	  Banerjee,	  Amro	  Aboukameel,	  Subhash	  Padhye,	  Philip	  A.	  Philip,	  Fazlul	  H.	  Sarkar,	  Anti-­‐Tumor	  Activity	  
of	   Novel	   Compound-­‐CDF	   Is	   Mediated	   by	   Regulating	   mir-­‐21,	   mir-­‐200,	   and	   PTEN	   in	  
Pancreatic	  Cancer.	  PLos	  ONE,	  2011.	  6(3):	  p.	  	  .	  52.	   Padhye,	  S.,	  et	  al,	  New	  difluoro	  Knoevenagel	  condensates	  of	  curcumin,	  their	  Schiff	  bases	  
and	  copper	  
complexes	   as	   proteasome	   inhibitors	   and	  apoptosis	   inducers	   in	   cancer	   cells.	   Pharmaceutical	  Research,	  2009.	  26(8):	  p.	  1874-­‐80.	  53.	   Dandawate,	  P.R.,	  et	  al.,	   Inclusion	  complex	  of	  novel	  curcumin	  analogue	  CDF	  and	  beta-­‐
cyclodextrin	   (1:2)	   and	   its	   enhanced	   in	   vivo	   anticancer	   activity	   against	   pancreatic	  
cancer.	  Pharm	  Res,	  2012.	  29(7):	  p.	  1775-­‐86.	  
	  	  
81	  
54.	   Sutton,	   D.,	   et	   al.,	   Functionalized	  micellar	   systems	   for	   cancer	   targeted	   drug	   delivery.	  Pharm	  Res,	  2007.	  24(6):	  p.	  1029-­‐46.	  55.	   Yokoyama,	   M.,	   Clinical	   Applications	   of	   Polymeric	   Micelle	   Carrier	   Systems	   in	  
Chemotherapy	   and	   Image	   Diagnosis	   of	   Solid	   Tumors.	   Journal	   of	   Experimental	   &	  Clinical	  Medicine,	  2011.	  3(4):	  p.	  151-­‐158.	  56.	   Loh,	  W.,	  BLOCK	  COPOLYMER	  MICELLES.	  Encyclopedia	  of	  Surface	  and	  Colloid	  Science,	  2002.	  57.	   Riess,	   G.,	   Micellization	   of	   block	   copolymers.	   Progress	   in	   Polymer	   Science,	   2003.	  
28(7):	  p.	  1107-­‐1170.	  58.	   Yokoyama,	   M.,	   Supramolecular	   Design	   for	   Biological	   Applications.	   Drug	   targeting	  with	  polymeric	  micelles	  drug	  carriers.	  2002:	  CRC	  Press.	  59.	   Sezgin,	  Z.,	  N.	  Yuksel,	  and	  T.	  Baykara,	  Preparation	  and	  characterization	  of	  polymeric	  
micelles	  for	  solubilization	  of	  poorly	  soluble	  anticancer	  drugs.	  Eur	  J	  Pharm	  Biopharm,	  2006.	  64(3):	  p.	  261-­‐8.	  60.	   Kataoka	  Kazunori,	  K.G.S.,	  Yokoyama	  Masayuki,	  Okano	  Teruo,	  Sakurai	  Yasuhisa,	  Block	  
copolymer	  micelles	  as	  vehicles	  for	  drug	  delivery.	  Journal	  of	  Controlled	  Release,	  1993.	  
24(1-­‐3):	  p.	  119-­‐132.	  61.	   Chris	   Oerlemans	   ,	   W.B.M.B.,	   Gert	   Storm,J.	   Frank	   W.	   Nijsen,	   Wim	   E.	   Hennink,	  
Polymeric	  Micelles	  in	  Anticancer	  Therapy:	  Targeting,	  Imaging	  and	  Triggered	  Release.	  Pharm	  Res,	  2010.	  27:	  p.	  2569-­‐2589.	  62.	   Brannon-­‐Peppas,	  L.	  and	  J.O.	  Blanchette,	  Nanoparticle	  and	  targeted	  systems	  for	  cancer	  
therapy.	  Advanced	  Drug	  Delivery	  Reviews,	  2012.	  64:	  p.	  206-­‐212.	  
	  	  
82	  
63.	   Orr,	   G.A.,	   et	   al.,	  Mechanisms	   of	   Taxol	   resistance	   related	   to	  microtubules.	   Oncogene,	  2003.	  22(47):	  p.	  7280-­‐95.	  64.	   A	   Stierle,	   G.S.,	   D	   Stierle,	  Taxol	   and	   taxane	  production	   by	  Taxomyces	   andreanae,	   an	  
endophytic	  fungus	  of	  Pacific	  yew.	  science,	  1993.	  260:	  p.	  214-­‐216.	  65.	   K,	  P.,	  Paclitaxel	  Against	  Cancer:	  A	  Short	  Review.	  Medicinal	  chemistry,	  2012.	  02(07).	  66.	   cancer	  drug	  information	  Paclitaxel,	  N.c.	  institute,	  Editor.	  2006.	  67.	   Paclitaxel.	   Available	   from:	  http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1411&ns=NCI_Thesaurus.	  68.	   Park	   S,	   K.S.,	   Chen	   X,	   Kim	   EJ,	   Kim	   J,	   Kim	   N,	   Kim	   J,	   Jin	   MM,	   Tumor	   suppression	   via	  
paclitaxel-­‐loaded	   drug	   carriers	   that	   target	   inflammation	   marker	   upregulated	   in	  
tumor	  vasculature	  and	  macrophages.	  BIomaterials,	  2013.	  34(2):	  p.	  598-­‐605.	  69.	   Jianan	  Shena,	  H.S.b.,	  Pengfei	  Xua,	  Qi	  Yina,	  Zhiwen	  Zhanga,	  Siling	  Wangb,	  Haijun	  Yua,	  Yaping	  Lia,	  Simultaneous	  inhibition	  of	  metastasis	  and	  growth	  of	  breast	  cancer	  by	  co-­‐
delivery	   of	   twist	   shRNA	   and	   paclitaxel	   using	   pluronic	   P85-­‐PEI/TPGS	   complex	  
nanoparticles.	  Biomaterials,	  2013.	  34(5):	  p.	  1581-­‐1590.	  70.	   Byron	   SA,	   L.D.,	   Pollock	   PM,	   Fibroblast	   growth	   factor	   receptor	   inhibition	   synergizes	  
with	   Paclitaxel	   and	   Doxorubicin	   in	   endometrial	   cancer	   cells.	   Int	   J	   Gynecol	   Cancer,	  2012.	  22(9):	  p.	  1517-­‐1526.	  71.	   T.	  Huang,	  W.H.G.,	  X.	  C.	  Li,	  C.	  P.	  Zou,	  G.	  J.	  Jiang,	  X.	  H.	  Li,	  D.	  P.	  Feng,	  Synergistic	  increase	  
in	   the	   sensitivity	   of	   osteosarcoma	   cells	   to	   thermochemotherapy	  with	   combination	   of	  
paclitaxel	  and	  etoposide.	  Molecular	  medicine	  reports,	  2012.	  6:	  p.	  1013-­‐1017.	  
	  	  
83	  
72.	   Yang	  JC,	  L.M.,	  Lee	  CL,	  Chen	  GY,	  Lin	  YY,	  Chang	  FR,	  Wu	  YC,	  Selective	  targeting	  of	  breast	  
cancer	  cells	  through	  ROS-­‐mediated	  mechanisms	  potentiates	  the	  lethality	  of	  paclitaxel	  
by	  a	  novel	  diterpene,	  gelomulide	  K.	  Free	  Radic	  Biol	  Med,	  2011.	  51(3):	  p.	  647-­‐657.	  73.	   H.	   Gelderblom*,	   J.V.,	   K.	   Nooter,	   A.	   Sparreboom,	   Cremophor	  EL:	   the	   drawbacks	   and	  
advantages	   of	   vehicle	   selection	   for	   drug	   formulation.	   European	   Journal	   of	   Cancer,	  2001.	  37:	  p.	  1590-­‐1598.	  74.	   <Nanocarriers	  as	  an	  emerging	  platform	  for	  cancer	  therapy.pdf>.	  75.	   Bellamy	  WT,	  D.W.,	  Multidrug	  resistance	  in	  the	  laboratory	  and	  clinic.	  Adv	  Clin	  Chem,	  1994.	  31:	  p.	  1-­‐61.	  76.	   Limtrakul,	  P.,	  Chearwae,	  W,	  Shukla,	  S,	  Phisalphong,	  C,	  Ambudkar,	  S.	  V,	  Modulation	  of	  
function	   of	   three	   ABC	   drug	   transporters,	   P-­‐glycoprotein	   (ABCB1),	   mitoxantrone	  
resistance	   protein	   (ABCG2)	   and	   multidrug	   resistance	   protein	   1	   (ABCC1)	   by	  
tetrahydrocurcumin,	   a	   major	   metabolite	   of	   curcumin.	   Mol.	   Cell.	   Biochem,	   2007.	  
296(1):	  p.	  85-­‐95.	  77.	   Amiji,	   S.G.a.M.,	   Coadministration	   of	   Paclitaxel	   and	   Curcumin	   in	   Nanoemulsion	  
Formulations	  To	  Overcome	  Multidrug	  Resistance	  in	  Tumor	  Cells.	  mol.Pharmaceutics,	  2009.	  6(3):	  p.	  928-­‐939.	  78.	   Mohsen	   Ashjari,	   S.K.,	   Ali	   Reza	   Mahdavian,	   Reza	   Rahmatolahzadeh,	   Self-­‐assembled	  
nanomicelles	   using	   PLGA–PEG	   amphiphilic	   block	   copolymer	   for	   insulin	   delivery:	   a	  
physicochemical	   investigation	   and	   determination	   of	   CMC	   values.	   J	   Mater	   Sci:	   Mater	  Med	  2012.	  23:	  p.	  943-­‐953.	  
	  	  
84	  
79.	   Ana	   Domínguez,	   A.F.n.,	   Noemí	   González,	   Emilia	   Iglesias,	   Luis	   Montenegro,	  
Determination	   of	   Critical	   Micelle	   Concentration	   of	   Some	   Surfactants	   by	   Three	  
Techniques.	  Journal	  of	  Chemical	  Education,	  1997.	  74(10).	  80.	   Chou,	  T.C.,	  Drug	  combination	  studies	  and	  their	  synergy	  quantification	  using	  the	  Chou-­‐
Talalay	  method.	  Cancer	  Res,	  2010.	  70(2):	  p.	  440-­‐6.	  81.	   Chou,	   T.C.,	   Theoretical	   basis,	   experimental	   design,	   and	   computerized	   simulation	   of	  
synergism	  and	  antagonism	  in	  drug	  combination	  studies.	  Pharmacol	  Rev,	  2006.	  58(3):	  p.	  621-­‐81.	  82.	   Ren,	  T.-­‐B.,	  et	  al.,	  Sheddable	  micelles	  based	  on	  disulfide-­‐linked	  hybrid	  PEG-­‐polypeptide	  
copolymer	  for	  intracellular	  drug	  delivery.	  Polymer,	  2011.	  52(16):	  p.	  3580-­‐3586.	  83.	   Verma,	   A.	   and	   F.	   Stellacci,	   Effect	   of	   surface	   properties	   on	   nanoparticle-­‐cell	  
interactions.	  Small,	  2010.	  6(1):	  p.	  12-­‐21.	  84.	   Li,	   J.,	  et	  al.,	  Redox-­‐sensitive	  micelles	  self-­‐assembled	  from	  amphiphilic	  hyaluronic	  acid-­‐
deoxycholic	   acid	   conjugates	   for	   targeted	   intracellular	   delivery	   of	   paclitaxel.	  Biomaterials,	  2012.	  33(7):	  p.	  2310-­‐20.	  85.	   Wang,	   K.,	   et	   al.,	   Novel	   shell-­‐cross-­‐linked	   micelles	   with	   detachable	   PEG	   corona	   for	  
glutathione-­‐mediated	  intracellular	  drug	  delivery.	  Soft	  Matter,	  2013.	  9(3):	  p.	  692.	  
 
 
 
 
 
 
	  	  
85	  
ABSTRACT 
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             Solid tumors like pancreatic tumor has unique property of forming a 
dense desmoplastic layer around the tumor cells making it difficult for the 
drug to transport across this layer. Multi drug resistance is also one of the 
major limitation of chemotherapy. Therefore the aim of this project was to 
make PLGA-SS-PEG micelles encapsulating CDF and paclitaxel for 
synergistic cancer therapy. CDF was found to have 16-fold better half-life 
when compared to curcumin maintaining equivalent bioactivity. Since CDF 
has chemosensitizing property we tested this by incorporating CDF and 
paclitaxel in same formulation and tested their synergy on BXPC3 
pancreatic cancer cell line and SKOV3 ovarian cancer cell line that is 
paclitaxel resistant. Here we utilized a number of techniques including 
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incorporation of PEG surface molecules thereby avoiding uptake by 
monophagocytic system and cysteine protease liable conjugation of PEG to 
the micelles making CDF and paclitaxel release specific to tumor tissue by 
enhanced permeation and retention effect. All the micelle formulations were 
below 200 nm size range. Our drug release study proved that these 
micelles undergo a fast sheddable process upon encountering the 
reduction sensitive condition like higher glutathione (GSH) levels. Cell 
cytotoxicity studies revealed the copolymer has good biocompatibility and 
self-assembled micelles showed drug loading of around 9 % for both the 
drugs and they released the drug quantitatively in response to the level of 
GSH. The synergistic effect was studied by Chou-Talalay method. There 
was a time and concentration dependent cell killing. Maximum synergy was 
observed at 72 h time point for BXPC3 cells and SKOV3 cells at 72 h time 
point with PLGA-S-S-PEG micelles coencapsulating both CDF and 
paclitaxel. The micelle formulation has higher synergy than compared to 
free drug combination in both cell lines at 72 hour time point. Overall IC50 
values of both CDF and paclitaxel were reduced when used in combination.  
Based on the results of our study it indicates that these micelles have a 
potential promote tumor penetration because of smaller size, prolonged 
circulation and EPR effect and release the drug specifically in tumor cells 
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upon exposure to highly reductive environment. Since these micelles 
incorporated two drugs they will be efficient for chemotherapy in multi drug 
resistant tumors. 
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